Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...
Looking at Pfizer's recent performance in business turnaround, I think the recovery in PFE stock should continue in the medium term - the 10% total return since June 2024 may be just the beginning ...